Method for detecting diseases or conditions in the central nervous system

Abstract

To provide novel methods for detecting diseases or conditions in the central nervous system, determining disease activity, and determining the effectiveness of treatment for diseases or conditions in the central nervous system. [Solution] According to the present invention, a method for detecting and determining disease activity of neurosarcoidosis, autoimmune GFAP astrocytopathy, immune-related adverse events (irAEs) in the central nervous system or SARS-CoV-2-related encephalomyelitis caused by the administration of immune checkpoint inhibitors, and a method for detecting neurosarcoidosis, autoimmune GFAP astrocytopathy, immune checkpoint inhibitors, and a method for determining disease activity, comprising the step of measuring the amount or concentration of CXCL10 in the cerebrospinal fluid of a target. A method is provided for determining the therapeutic effect of cytoplasmic encephalomyelitis (IRAEs) in the central nervous system or SARS-CoV-2-related encephalomyelitis caused by the administration of cytoplasmic encephalomyelitis inhibitors.

Claims

1. A cerebrospinal fluid sample of a target cerebrospinal fluid sample comprising the step of measuring the amount or concentration of CXCL10 in the sample. Transsarcoidosis, autoimmune GFAP astrocytopathy, immune checkpoint Immune-related adverse events (irAEs) or SAs in the central nervous system caused by the administration of inhibitors A method for detecting RS-CoV-2-associated encephalomyelitis.

2. The amount or concentration of CXCL10 in the target cerebrospinal fluid sample is used as an indicator to determine neurosarcoid Cis, autoimmune GFAP astrocytopathy, the aforementioned immune-related side effects or SARS- The test according to claim 1, further comprising the step of determining whether or not CoV-2-related encephalomyelitis has developed. How to get out.

3. The process involves comparing the amount or concentration of CXCL10 in the target cerebrospinal fluid sample with a reference value. The detection method according to claim 1 or 2, which includes the above.

4. Reference values ​​include neurosarcoidosis, autoimmune GFAP astrocytopathy, and the aforementioned immunodeficiency Cerebrospinal fluid from subjects who have not developed disease-related adverse reactions or SARS-CoV-2-associated encephalomyelitis. The value is set based on the amount or concentration of CXCL10 in the sample, according to claims 1 to 3. The detection method described in item 1.

5. Immune checkpoint inhibitors include anti-PD-1 antibodies, anti-PD-L1 antibodies, and anti-CTLA-4 antibodies. From antibodies, anti-LAG-3 antibodies, anti-TIM-3 antibodies, anti-TIGIT antibodies, and anti-KIR antibodies One or more selected from the group, according to any one of claims 1 to 4. Detection method.

6. The detection according to claim 5, wherein the anti-PD-1 antibody is pembrolizumab or nivolumab. method.

7. A cerebrospinal fluid sample of a target cerebrospinal fluid sample comprising the step of measuring the amount or concentration of CXCL10 in the sample. Transsarcoidosis, autoimmune GFAP astrocytopathy, immune checkpoint Immune-related adverse events (irAEs) or SAs in the central nervous system caused by the administration of inhibitors Method for determining disease activity in RS-CoV-2-associated encephalomyelitis.

8. The amount or concentration of CXCL10 in the target cerebrospinal fluid sample is used as an indicator to determine neurosarcoid Cis, autoimmune GFAP astrocytopathy, the aforementioned immune-related side effects or SARS- The judgment according to claim 7, further comprising the step of evaluating the disease activity of CoV-2-associated encephalomyelitis. method.

9. A cerebrospinal fluid sample of a target cerebrospinal fluid sample comprising the step of measuring the amount or concentration of CXCL10 in the sample. Transsarcoidosis, autoimmune GFAP astrocytopathy, immune checkpoint Immune-related adverse events (irAEs) or SAs in the central nervous system caused by the administration of inhibitors A method for evaluating the effectiveness of treatment for RS-CoV-2-associated encephalomyelitis.

10. The amount or concentration of CXCL10 in the target cerebrospinal fluid sample is used as an indicator to determine neurosarcoid Cis, autoimmune GFAP astrocytopathy, the aforementioned immune-related side effects or SARS- Claim 9 further includes a step of evaluating the degree of therapeutic effect against CoV-2-associated encephalomyelitis. The determination method described above.

11. The process involves comparing the amount or concentration of CXCL10 in the target cerebrospinal fluid sample with a reference value. The determination method according to claim 9 or 10, which is included in the above.

12. The reference value is determined based on the amount or concentration of CXCL10 in the subject's cerebrospinal fluid sample before treatment. The determination method according to claim 11, wherein the value is a predetermined value.

13. Neurosarcoidosis, autoimmune GFAP astrocytopathy, immune checkpoint Immune-related adverse events (irAEs) in the central nervous system caused by the administration of inhibitors or Use of CXCL10 as a diagnostic marker for SARS-CoV-2-associated encephalomyelitis.

14. A means for quantifying CXCL10 in a cerebrospinal fluid sample, for neurosarcoidosis, auto Immuno-induced GFAP astrocytopathy, caused by the administration of immune checkpoint inhibitors. Immune-related adverse events (irAEs) in the central nervous system or SARS-CoV-2-related brain and spinal cord syndrome Diagnostic kit for myelitis.

Images